Filing
1st Quarter - Report
Lobbying activity
3
Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases.
Matters affecting plasma donation and potential plasma shortages. Issues related to PAHPA.
Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.